Author:
Khasabova Iryna A.,Yao Xu,Paz Justin,Lewandowski Cutler T.,Lindberg Amy E.,Coicou Lia,Burlakova Natasha,Simone Don A.,Seybold Virginia S.
Funder
National Institutes of Health
DA07234
University of Minnesota Undergraduate Research Opportunities Program
Reference47 articles.
1. American Society for Clinical Oncology; 2014. www.cnn.com/2014/03/11/health/cancer-care-asco-report/.
2. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects;Florea;Cancers (Basel),2011
3. Cisplatin neuropathy, risk factors, prognosis, and protection by WR-2721;Mollman;Cancer,1988
4. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity;Gregg;J Clin Oncol,1992
5. Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotheraphy;Khasabova;J. Neurosci,2012